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A B S T R A C T   
Recently, we have reported cardiovascular protective effects of the probiotic kefir in a model of primary hy-
pertension. Now, we evaluated the beneficial effects of kefir in a model of secondary hypertension under hy-
peractivation of the renin-angiotensin-system by partially clipping one kidney artery (2K1C) for 60 days and 
compared with Sham rats. Maximum levels of arterial pressure were reached 7–14 days post-clipping in both 
2K1C and 2K1C-Kefir, but after that time the values were approximately 20% lower in 2K1C-Kefir rats. Also, 
kefir attenuated the angiotensin converting enzyme activity (intrarenal-40%/plasma-25%) preventing the in-
crease of angiotensin II in both samples. Isolated aortic rings showed an impaired relaxation to acetylcholine in 
2K1C (-38%) compared to the Sham group and this difference was attenuated in 2K1C-Kefir rats (~15%). 
Additional analysis revealed that kefir protected kidney and vascular endothelium against the synergistic oxi-
dative stress/angiotensin II-axis. Thus, kefir is an effective nutraceutical therapy for prevention/treatment of 
hypertension.   
1. Introduction 
Hypertension is a common cardiovascular disease worldwide, 
characterized by persistent high arterial pressure, and is the main single 
contributor to all-cause disability and mortality (GBD, 2017; Kotchen, 
2011; Oparil et al., 2018). Classically, it is known that endothelial 
dysfunction is a main marker of this disease, contributing directly to 
myriad pathophysiological outcomes (e.g., heart failure, stroke, chronic 
kidney disease, retinopathy) (Dias et al., 2018; Oparil et al., 2018; 
Vasquez, Pereira, Peotta, Baldo, & Campos-Toimil, 2019). While most 
patients develop hypertension due to an unknown cause (classified as 
essential or primary hypertension), the remaining patients (5–10%) 
have secondary hypertension, which is caused by other known patho-
physiologic processes (Chokshi, Grossman, & Messerli, 2013; Mills, 
Stefanescu, & He, 2020). 
Renovascular hypertension (RH) is one of the most common types of 
secondary hypertension with different pathophysiological triggers and 
mainly affects children and elderly people (Herrmann & Textor, 2019; 
Wells & Belsha, 1996). This disease is characterized by renal hypo-
perfusion and consequent hyperactivation of the renin-angiotensin 
system (RAS), culminating in an excessive production of reactive 
oxygen species (ROS), sympathoexcitation, and arterial and renal 
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damage, leading to multidrug-resistant hypertension culminating in 
high morbimortality (Campos et al., 2011; Herrmann & Textor, 2019; 
Mehta & Fenves, 2010; Pereira et al., 2009). Thus, studies that in-
vestigate new therapeutic approaches to counteract the progression of 
RH are relevant, especially those addressing inexpensive approaches 
with minimal side effects. 
Experimental RH was induced by Goldblatt in 1934 through uni-
lateral partial stenosis of the renal artery in dogs, referred to as the two- 
kidney, one-clip (2K1C) model (Goldblatt, Lynch, Hanzal, & 
Summerville, 1934; Kotchen, 2011). In the last four decades, 2K1C has 
been an attractive model for studies in the hypertension field and has 
been used by our laboratory (Cabral & Vasquez, 1991; Dias et al., 2018; 
Moyses, Cabral, Marçal, & Vasquez, 1994; Pereira et al., 2009) and 
others (Campos et al., 2011; Campos, Oliveira-Sales, Nishi, Paton, & 
Bergamaschi, 2015; Navar et al., 1998; Oliveira-Sales et al., 2008) to 
investigate cardiac and vascular morphological changes, the interrela-
tions among RAS, oxidative stress (generated by excessive ROS), en-
dothelial dysfunction and sympathomodulation in addition to de-
termining the possible preclinical efficacy of therapeutic candidates. 
Among the varieties of functional foods available, kefir, a fermented 
milk containing lactic acid bacteria and yeasts, has been extensively 
studied for its beneficial effects, including its cardiovascular effects 
(Amorim et al., 2019; Friques et al., 2015; Pimenta et al., 2018; Rosa 
et al., 2017; Santanna et al., 2016). Recently, kefir was tested by our 
research group in spontaneously hypertensive rats (SHRs), a classical 
model for essential hypertension. We observed significant improve-
ments in endothelial dysfunction and baroreflex control, in addition to 
the antihypertensive effects (de Almeida Silva, Mowry, Peaden, 
Andrade, & Biancardi, 2020; Friques et al., 2015; Klippel et al., 2016; 
Vasquez, Aires, Ton, & Amorim, 2020), by at least promoting inhibitory 
actions on the RAS and oxidative stress (Amorim et al., 2019; Friques 
et al., 2020). However, the detailed effects of kefir on endothelial 
dysfunction and related parameters in the 2K1C model have not yet 
been investigated. Therefore, this study was designed to test the hy-
pothesis that kefir may have renal and vascular protective effects in 
2K1C rats, antagonizing the synergistic oxidative stress/angiotensin II 
axis. 
2. Materials and methods 
2.1. Animals 
The experiments were conducted in 138 male Wistar rats 
(140–160 g) provided by the Experimental Animal Care of Federal 
University of Espirito Santo, Brazil. All animals were kept in clean 
polypropylene cages in a constant light-dark cycle of 12 h, temperature 
from 20 to 25 °C, humidity of 70% prior to the start of experiments and 
during the 60 days of treatment. Animals were provided with ad libitum 
water and standard diet pellets until the treatment was completed. The 
experimental protocol was established according to the ethical princi-
ples of the research with animals by the National Technical Commission 
on Biosafety (CTNBio) and the Ethics Committee on the Use of 
Experimental Animals (CEUA-UFES, protocol # 489-2018). 
2.2. Preparation and administration of kefir 
Kefir was prepared as previously described (Friques et al., 2015). 
Briefly, the kefir grains, obtained from the University of Vila Velha 
since 2014 (Brazil), were added to whole milk, pasteurized, and cooled 
in a ratio of 4% (w/v). The milk inoculated with the grain was kept at 
room temperature for 24 h. After this period, the grain was filtered 
through a plastic sieve, and the resulting product was kept under re-
frigeration at between 5 and 15 °C for 24 h for the yeasts to multiply. At 
the end of this process, the kefir was aliquoted into sterile plastic tubes 
and stored at −20 °C until use. 
The rats were randomly assigned to three experimental groups: 
sham-operated normotensive (Sham, n = 4–8/protocol), RH induced 
by clipping the left renal artery (2K1C, n = 4–8/protocol) and 2K1C 
rats administered kefir (2K1C-Kefir, n = 4–8/protocol). The dosing and 
administration of kefir were in accordance with our previous studies 
(Friques et al., 2015, 2020; Klippel et al., 2016). The 2K1C-Kefir group 
received kefir at a dose of 0.3 mL/100 g body weight/day (corre-
sponding to human-equivalent doses of approximately 30 mL/70 kg/ 
day, according to Reagan-Shaw, Nihal, and Ahmad (2008) and Nair and 
Jacob (2016), while the 2K1C animals received whole milk at an ad-
justed pH of 4.3. The doses were given by gavage daily for 60 days, 
starting after surgery on the same day. 
2.3. Induction of 2K1C renovascular hypertension 
2K1C renovascular hypertension was induced as previously de-
scribed by our group (Cabral & Vasquez, 1991; Lincevicius et al., 2017; 
Shimoura et al., 2017). Briefly, under anesthesia with ketamine/xyla-
zine (90 and 10 mg/kg, respectively, i.p.), the left renal artery was 
exposed through a retroperitoneal flank incision, and after careful iso-
lation from the renal vein, nerves, and connective tissues, it was par-
tially obstructed with a silver clip 0.2 mm wide placed around the renal 
artery near the abdominal aorta. Age-matched rats of the Sham group 
were subjected to the same procedure but without the placement of the 
clip. The incision was sutured, and the animals were housed in in-
dividual climatized cages (up to 20 days). After observation of a com-
plete closure of the laparotomy incision, the rats were divided into 
cages containing 3 animals until the end of the study. The inclusion 
criterion in the 2K1C and 2K1C-Kefir groups was determined by ani-
mals that presented systolic arterial pressure measured by the tail-cuff 
method higher than 160 mmHg 7 days after surgery. 
2.4. Hemodynamic parameters and measurement of cardiac and renal mass 
Systolic arterial pressure was measured in conscious animals from 
day 0 (before surgery) to day 60 (end of treatment) by a noninvasive 
plethysmograph method following the protocol previously described 
(Friques et al., 2015). In addition, at the end of treatment with kefir, the 
animals were catheterized for direct measurements of AP. The rats were 
anesthetized with a combination of ketamine and xylazine (75 and 
10 mg/kg, respectively, i.p.), and a catheter was inserted aseptically 
into the femoral artery to determine the direct hemodynamic para-
meters: systolic, mean and diastolic arterial pressure. One day after 
catheter placement, hemodynamic parameters were measured in con-
scious, freely moving rats in their cages using a disposable AP trans-
ducer (Cobe Laboratories, USA) connected to a pressure processor 
amplifier and data-acquisition system (MP100, Biopac Systems, USA). 
The data were analyzed on a beat-to-beat basis to quantify the baseline 
values of AP. Then, the rats were euthanized with a sodium thiopental 
injection (100 mg/kg, i.p.) Cardiac and renal hypertrophy were eval-
uated based on the left ventricle heart weight (mg) to tibia length (mm) 
ratio and the clipped to nonclipped weight ratio, as previously de-
scribed (Klippel et al., 2016; Pereira et al., 2009). 
2.5. Evaluation of angiotensin converting enzyme (ACE) activity in blood 
samples 
After euthanasia of animals, kidneys were removed, immediately 
frozen in liquid nitrogen and subsequently stored in a freezer at −80 °C 
until sample preparation. In addition, blood was collected through the 
right ventricle using a syringe containing 100 µL of EDTA-free protease 
inhibitor cocktail (P2714, Sigma Aldrich, St. Louis, MO, US) and cen-
trifuged, and the plasma was divided into aliquots and stored at 
−80 °C. For ACE activity determination, triplicate plasma samples 
(3 μL) were incubated for 15 min at 37 °C with 40 μL of solution con-
taining the ACE substrate (Zphe-His Leu, 5 mM), sodium borate buffer 
(400 mM, pH 8.3) and NaCl (900 mM). For kidney analysis, each kidney 
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was homogenized in buffer (1:10 w/v, 100 mM Tris-HCl, 50 mM NaCl, 
pH 7.0). After homogenization, all samples were centrifuged (1000g) 
for 15 min at 4 °C. The product generated in the supernatant (His-Leu) 
was measured fluorimetrically (Synergy 2, Biotek, US) after 10 min of 
incubation with 17 μL of 2% o-phthaldialdehyde in methanol. The 
enzymatic reaction was stopped by the addition of 190 μL of 340 mM 
NaOH. Fluorescence measurements were performed at 37 °C on a 96- 
well black reading plate (black polystyrene, Corning, U.S.A.) with 
365 nm excitation and 495 nm emission filters. The fluorescent reading 
plate was controlled by Gen5 software (BioTek, USA). A calibration 
curve with ECA substrate was included on each plate. The “blank” 
samples contained 40 μL of ‘plasma buffer’ (5 mM ECA substrate, 
400 mM sodium borate buffer and 900 mM NaCl pH 8.3) or ‘kidney 
buffer’ (100 mM Tris-HCl, 50 mM NaCl, pH 7.0), plus 190 μL of 340 mM 
NaOH and 17 μL of o-phthaldialdehyde in methanol. The average va-
lues are shown as nmol/min/mL for serum and as nmol/min/mg pro-
tein for tissue homogenate. The protein measurement was performed by 
the Bradford method (Bradford, 1976). 
2.6. Measurement of angiotensin II levels 
The plasma and intrarenal levels (previously homogenized) of Ang 
II were measured via high-performance liquid chromatography (HPLC) 
at the Department of Nephrology at Unifesp as previously reported 
(Dias et al., 2018). Ang II was purified and extracted using an Oasis C18 
column (Water Corporation, Milford, MA) that was previously activated 
with methanol (5 mL), tetrahydrofuran (5 mL), hexane (5 mL) and 
distilled water (10 mL). Subsequently, the samples were eluted in col-
umns under a mixture of ethanol/acetic acid/water (at proportions 90% 
– 4% – 6%). The eluates were lyophilized and resuspended in 500 μL of 
mobile phase A (5% acetonitrile in 0.1% phosphoric acid) and then 
filtered with a 0.22 μm membrane for HPLC analysis. After the se-
paration of peptides in each sample using a reversed-phase column 
Aquapore 300 ODS (250 × 4.6 mm, PerkinElmer's Brownlee Columns, 
Norwalk, USA) with 5 min of isocratic gradient followed by 20 min of 
linear gradient from 5% to 35% of mobile phase B (95% acetonitrile in 
0.1% trifluoacetic acid) under a flow of 1.5 mL/min for 40 min by 
HPLC, Ang II was identified according to the retention period (< 6%) 
and height (< 5%) using a standard curve of known concentration, and 
the values of dosages in the kidney were normalized according to the 
kidney weight. 
2.7. Scanning electron microscopy 
Considering previous findings demonstrating vascular and renal 
structural changes in arterial hypertension models (Dias et al., 2018; 
Freitas et al., 2016; Leal et al., 2020), we analyzed the aorta micro-
architecture and nephron apparatus integrity through scanning electron 
microscopy. Euthanized animals were perfused with a solution of par-
aformaldehyde (2%), glutaraldehyde (2.5%) and cacodylate buffer so-
lution (0.1 mol/L, pH 7.2), and later, the kidneys were dissected and 
fixed in this solution for 24 h. The tissues were washed with 0.1 mol/L 
cacodylate buffer (pH 7.2–7.4). Subsequently, samples were postfixed 
in a solution of 2.0% osmium tetroxide (1.25% in water) of potassium 
ferrocyanide (2.5% + 0.2 M cacodylate buffer) for 1 h at room tem-
perature, and a second wash with 0.1 mol/L cacodylate buffer (pH 
7.2–7.4) was performed. Then, the samples were subjected to a cryo-
fracture procedure, where a few drops of glycerol (30% in 0.1 mol/L 
cacodylate buffer) were added to the postfixed samples. The drops were 
added at 5 min intervals so that at the end of 30 min, the initial volume 
contained in the Eppendorf vials with the samples was folded. After 3 h, 
the liquid was discarded, and the samples were stored in a freezer at 
−80 °C until the day after, when the samples were dipped in liquid 
nitrogen for cryofractures. After fixation, the cuts were dehydrated in 
ascending grades of ethanol, critical-point dried and coated with gold. 
The preparations were processed for images using a scanning electron 
microscope (Jeol, JEM6610 LV, Jeol Inc. USA). 
2.8. Vascular reactivity 
After euthanasia, vascular reactivity was evaluated in isolated 
thoracic aortas as previously described in detail (Friques et al., 2015; 
Leal et al., 2020). After the equilibration period, a contraction was in-
duced by the addition of phenylephrine (1 µM). Once the contraction 
stabilized, cumulative concentrations of acetylcholine (ACh, 10-11 to 
10−4.5 log mol/L) were added to the bath to assess the endothelial 
integrity of the preparations. The vasorelaxation response to ACh was 
expressed as the percentage of vasodilation relative to the maximal 
phenylephrine-induced precontraction level, and for each curve, the 
maximum effect and the sensitivity were calculated using nonlinear 
regression analysis. 
In some experiments, the rings were preincubated for 20 min with 
the following drugs: N(G)-nitro-l-arginine methyl ester (L-NAME, 
100 μmol/L), a nonspecific NO synthase inhibitor; apocynin (100 μmol/ 
L), a nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
inhibitor; or indomethacin (10 μmol/L), a nonspecific inhibitor of cy-
clooxygenase (Cox) 1 and 2, to evaluate their effects on ACh-induced 
relaxation. To verify whether the changes observed in ACh were in fact 
mediated by endothelium, sodium nitroprusside (SNP, 10-10 to 10-5 
mol/L), an NO donor, was used to test the responsiveness of vascular 
smooth cells. 
2.9. Determination of ROS in erythrocytes and aorta 
Flow cytometry was performed using a FACS Canto II (Becton 
Dickinson - BD, CA, USA) instrument to quantify the endothelial cells 
and analyze the intracytoplasmic ROS content. For endothelial cell 
counting, the animals were anesthetized as described above, and the 
aortic arch was isolated, minced and digested using type II collagenase 
(1000 U/mL, at 37 °C for 60 min under constant shaking). The tissue 
fragments were removed by filtration using a sterile 70-μm nylon mesh. 
The free cells were immediately washed twice in PBS to remove excess 
collagenase, and the cell suspension was stored at −80 °C. The number 
of endothelial cells in the aortas was determined using an APC-con-
jugated monoclonal antibody against platelet endothelial cell adhesion 
molecule (CD31-APC). Briefly, 1 × 105 cells were resuspended in PBS 
and incubated with 5 μL of CD31-APC or the respective isotype control 
in the dark (20 min, RT). From each sample, 100,000 events were ac-
quired and processed using FACS Diva software (Becton Dickinson - BD, 
CA, USA). 
The intracytoplasmic ROS content was determined in isolated en-
dothelial cells, as previously described (Friques et al., 2015). In-
tracellular superoxide anion (%O2−) and hydrogen peroxide (H2O2) 
were monitored separately by measuring changes in the median fluor-
escence intensity (MFI) emitted by dihydroethidium (DHE) and di-
chlorofluorescein (DCF), respectively. Briefly, 106 cells were incubated 
with 160 mmol/L DHE or 20 mmol/L DCF at 37 °C for 30 min (DHE, 
DCF) in the dark. The samples were then washed, resuspended in PBS 
and kept on ice until the acquisition of 10,000 events by flow cyto-
metry, which were subsequently analyzed using FCS Express software 
(De novo, USA). 
2.10. Data and biostatistical analysis 
The values are expressed as the mean  ±  SEM. For each con-
centration-response curve, the maximum effect (Rmax) and the molar 
concentration of compound required to elicit 50% of maximum re-
laxation (EC50) were calculated by nonlinear regression analysis using 
the nonlinear fitting function of Prism software (Prism 8, GraphPad 
Software, Inc., San Diego, CA, USA). The sensitivities of phenylephrine 
precontracted rings to ACh or SNP were calculated using the pEC50 
(−log EC50). The differences in the area under the curves (ΔAUC) were 
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calculated using the responses of the aortic rings before and after the 
presence of the inhibitor, and these results were expressed in arbitrary 
units (a.u.). 
Considering that our samples had a normal distribution, the statis-
tical comparisons between the different groups were performed by ei-
ther one-way or two-way analysis of variance (ANOVA) for repeated 
measures or completely randomized, followed by Bonferroni’s post hoc 
test. The statistical analyses were performed using Prism software. A 
value of p  <  0.05 was considered statistically significant. 
2.11. Drugs and chemicals 
Acetonitrile, apocynin, ACh, cacodylate, DHE, DCF, indomethacin, 
L-NAME, o-phthaldialdehyde, osmium tetroxide, paraformaldehyde, 
glutaraldehyde, phenylephrine, potassium ferrocyanide, SNP, sodium 
cacodylate, tetrahydrofuran and Tris-HCl were purchased from 
Sigma–Aldrich (St. Louis, MO, USA). Sodium thiopental (Thipentax®) 
was obtained from Bayer (Germany) and Cristalia (São Paulo, Brazil). 
All other chemical solvents used were of analytical grade. 
3. Results 
3.1. Kefir reduces blood pressure in renovascular hypertensive rats 
Fig. 1A shows the average values of the resting systolic, mean and 
diastolic arterial pressure measurements in conscious animals 60 days 
after renal artery clipping. As expected, 2K1C rats developed hy-
pertension compared to the Sham group (systolic: 205  ±  7 vs. 
139  ±  6 mmHg; mean: 171  ±  6 vs. 95  ±  2 mmHg; diastolic: 
130  ±  4 vs. 69  ±  5 mmHg, p  <  0.05). The novel result was that 
kefir supplementation demonstrated antihypertensive effects in 2K1C 
rats, as observed through systolic, mean and diastolic arterial pressure 
(reduction by 13%, 23% and 30%, respectively, p  <  0.05). Interest-
ingly, periodic noninvasive systolic arterial pressure revealed that the 
prevention of hypertension using kefir was consolidated from the 28th 
day of supplementation with a reduction of 13% (2K1C: 227  ±  9 vs. 
2K1C-kefir: 198  ±  9 mmHg, p  <  0.05, Fig. 1B), extending to 45th 
and 60th days (reduction by 13% and 16%, respectively p  <  0.05). 
3.2. Determination of ACE activity and angiotensin II (plasma and 
intrarenal) 
The average values in Fig. 2 show that after 60 days of RH, ACE 
activity was increased in both plasma (~20%) and intrarenal samples 
(nonclipped kidney: 24% and clipped kidney: 43%) of 2K1C rats com-
pared to the normotensive Sham group (p  <  0.05). The novel result 
was that treatment with kefir was able to significantly reduce ACE ac-
tivity in the three target sites (plasma: 24%; nonclipped and clipped 
kidney: 40%, p  <  0.05), suggesting that this probiotic may also reduce 
the production of Ang II. Confirming our hypothesis, we observed that 
Ang II levels were significantly reduced in both plasma and tissues from 
nonclipped and clipped kidneys in the 2K1C rats treated with kefir 
(54%, 50% and 35%, respectively) compared with the nontreated 2K1C 
group (p  <  0.05). 
3.3. Effects of kefir on the morphological alterations induced by renal 
clipping in the left ventricle and kidney 
The classical changes in the mass of cardiac ventricles (hyper-
trophy) and clipped (atrophy) and nonclipped (hypertrophy) kidneys 
Fig. 1. Kefir reduced renovascular hypertension in 2K1C rats. Invasive measurements of arterial pressure (systolic, mean and diastolic, N = 8/group) (A) and 
noninvasive systolic values in conscious Sham, 2K1C and 2K1C-Kefir rats (N = 8/group) (B). Bar graphs show that kefir did not attenuate left ventricular hypertrophy 
(N = 6/group) (C) and did not prevent renal atrophy, as observed in typical macroimages (D) or bar graphs (N = 6/group) (E). Values are the mean  ±  SEM. 
*p  <  0.05 vs. Sham group and #p  <  0.05 vs. 2K1C group; one-way (bar graphs) or two-way (line graph) ANOVA. 
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that occur in the rat model of RH were confirmed in the present study 
(Fig. 1C–E). Despite the antihypertensive effect exhibited by kefir in the 
renovascular hypertensive group, kefir was not effective in mitigating 
left ventricular hypertrophy (2K1C: 5.9  ±  0.2 vs 2K1C-kefir: 
5.5  ±  0.5 mg/mm, p  >  0.05) compared to the values in the Sham 
(Sham: 4.3  ±  0.2 mg/mm, p  <  0.05, Fig. 1C) or renal atrophy (2K1C: 
0.22  ±  0.1 vs 2K1C-kefir: 0.24  ±  0.04 mg/nonclipped kidney, 
p  >  0.05, Fig. 1D and E) groups. 
The morphological analysis of the ultrastructure of the kidneys 
performed by scanning electron microscopy is shown in Fig. 3. In the 
nontreated 2K1C group, some typical damage in the renal glomerulus, 
podocytes and tubules was noted compared to the Sham group. Kefir 
treatment apparently reduced kidney damage, maintaining morpholo-
gical characteristics similar to those in the Sham group. 
3.4. Kefir reduces aortic endothelial dysfunction in 2K1C hypertensive rats 
Due to the magnitude of endothelial dysfunction in the 2K1C group, 
we decided to use some animals from each group (n = 4 per group) to 
evaluate the typical damage to the architecture of the endothelial sur-
face. As expected, scanning electron micrographs (Fig. 4) of the thoracic 
aortas from normotensive animals showed a confluent endothelial cell 
layer. In contrast, the 2K1C group exhibited gaps between endothelial 
cells, with clear damage to the luminal surface layer exposing the in-
ternal elastic membrane. Interestingly, the 2K1C animals treated with 
kefir (60 days) exhibited a better-preserved endothelial surface than 
non-treated 2K1C and showed no gaps. 
Fig. 2. Values of plasma and intrarenal (nonclipped and clipped kidney) angiotensin II in Sham, 2K1C renovascular hypertensive rats, and 2K1C rats treated with 
kefir. Each value represents the mean  ±  SEM (N = 6–8). *p  <  0.05 vs. Sham group; #p  <  0.05 vs. 2K1C group (one-way ANOVA). 
Fig. 3. Effects of kefir on kidney microstructures of renovascular hypertensive rats. Typical photomicrographs of the left kidney obtained by scanning electron 
microscopy showing glomeruli, podocytes, and renal tubules. Red arrows show sites of damage in architecture of the kidney, mainly observed in the clipped and 
nonclipped kidneys of 2K1C hypertensive rats. Yellow arrows suggest well-preserved structures in the kidney of Sham rats and in hypertensive rats treated with kefir 
(N = 5–6). Horizontal bars indicate the relative magnification. (For interpretation of the references to colour in this figure legend, the reader is referred to the web 
version of this article.) 
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3.5. Kefir reduces aortic endothelial dysfunction in 2K1C hypertensive rats 
To evaluate the physiological conditions of endothelial function in 
the aortic rings, we first evaluated vascular responsiveness to 3 classical 
agents: ACh (to test endothelium-dependent relaxation in pheny-
lephrine-precontracted vessels), the direct NO donor SNP (to test en-
dothelium-independent relaxation) and phenylephrine (to investigate 
the contractile response). 
Fig. 5 shows that ACh-induced relaxation was significantly impaired 
in the 2K1C group compared to the Sham group (Rmax: 50  ±  3% and 
81  ±  2%, respectively, p  <  0.05). Treatment with kefir for 60 days 
caused a marked reduction in that difference (Rmax for the 2K1C-kefir 
group: 68  ±  3%, p  <  0.05 vs. 2K1C group), although this value was 
still statistically reduced with respect to the Sham group (p  <  0.05). 
The 2K1C group also exhibited a significant decrease in the sensitivity 
to ACh compared to that in the Sham group (pEC50: 6.8  ±  0.2 vs. 
7.5  ±  0.1, respectively, p  <  0.05), and kefir was able to abolish that 
difference (pEC50 for the 2K1C-Kefir group: 7.5  ±  0.1, p  >  0.05 with 
respect to the Sham group). 
The endothelium-independent relaxation was tested using SNP (10-10 
to 10-5 mol/L). As shown in the middle graph of Fig. 5, the relaxant effect 
of this direct NO donor was significantly reduced in the 2K1C group 
compared to the Sham group (Rmax: 86  ±  3 and 95  ±  1%, respectively, 
p  <  0.05), although this reduction was of a lower magnitude than that 
observed with ACh. Kefir treatment completely prevented that alteration 
(Rmax for the 2K1C-Kefir group: 90  ±  2%, p  <  0.05 vs. 2K1C). There 
was also a significant reduction in the sensitivity to ACh in the 2K1C 
hypertensive animals in comparison to the Sham group (pEC50: 
7.1  ±  0.1 and 8.0  ±  0.1, respectively, p  <  0.05). However, 2K1C-Kefir 
showed no difference in sensitivity to ACh when compared to the 2K1C 
group (pEC50: 7.7  ±  0.1, p  >  0.05). Therefore, treatment with kefir did 
not change muscle dysfunction in 2K1C animals. 
As seen in the right graph in Fig. 5, the aortic rings of the 2K1C group 
were hyperreactive to phenylephrine (Rmax: 85  ±  1%) compared to 
those of the Sham group (Rmax: 74  ±  2%, p  <  0.05). Additionally, kefir 
treatment reduced vascular hyperreactivity (Rmax: 78  ±  2%). On the 
other hand, 2K1C-Kefir group showed no difference in the sensitivity to 
phenylephrine compared to the 2K1C or Sham groups (6.2  ±  0.1%; 
6.2  ±  0.1%; 6.1  ±  0.15, respectively, p  >  0.05). 
3.6. Kefir restores NO bioavailability in 2K1C hypertensive rat aorta 
The contribution of NO bioavailability to endothelial dysfunction in 
2K1C cells and to the effect of kefir was evaluated using L-NAME 
(Fig. 6, Table 1). To achieve this goal, we calculated the average values 
of the maximum response, pEC50 (negative logarithm of required 
concentration to produce 50% of the maximum response – ‘sensitivity’) 
and the difference in the area under the curve (ΔAUC) from the con-
centration-response curve obtained during the blockade of the basal 
NO/cGMP molecular pathway with L-NAME. Interestingly, preincuba-
tion with this NOS inhibitor abolished the vasorelaxation induced by 
ACh in all 3 experimental groups (Fig. 6). 
NOS blockade with L-NAME caused intense changes in the Rmax of 
concentration–response curves to ACh in the Sham (from 81  ±  8% to 
−1.1  ±  0.3%) and 2K1C (from 50  ±  4 to 5.4  ±  0.4%) groups and in 
the hypertensive rats treated with kefir (from 62  ±  7% to 
Fig. 4. Effects of kefir on the mor-
phology of aortic vessels in re-
novascular hypertensive rats. Typical 
cross-section photomicrographs of the 
aorta obtained by scanning electron 
microscopy. Bottom images indicated 
by yellow arrows are magnifications of 
the endothelial surface. Suggestive da-
mage to the endothelial surface in the 
2K1C rat is indicated by red arrows 
lacking cellularity. (For interpretation 
of the references to colour in this figure 
legend, the reader is referred to the web 
version of this article.) 
Fig. 5. Effects of kefir on vascular reactivity 
in renovascular hypertensive rats. 
Relaxation induced by cumulative con-
centrations of ACh (A) and SNP (B) in phe-
nylephrine (1 µM) precontracted rings and 
contraction induced by cumulative con-
centrations of phenylephrine (C). Sham: 
control normotensive rats; 2K1C: re-
novascular hypertensive rats; 2K1C-Kefir: 
renovascular hypertensive rats treated with 
kefir. Each point represents the 
mean  ±  SEM of 8 experiments. Statistical 
significance: *p  <  0.05 vs. Sham group; 
#p  <  0.05 vs. 2K1C group (two-way re-
peated measures ANOVA). 
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7.2  ±  0.7%). The ΔAUC was smaller in the 2K1C group (ΔAUC: 
155  ±  9 a.u.), in comparison with Sham animals (AUC: 255  ±  11 
a.u., p  <  0.05), and this value was restored by treatment with kefir 
(ΔAUC for the 2K1C-Kefir group: 247  ±  8 a.u., p  <  0.05. The sen-
sitivity was significantly altered only in the Sham (7.3  ±  0.4 to 
5.5  ±  0.4) and 2K1C-Kefir (from 7.8  ±  0.5 to 10  ±  0.3) groups but 
not in the 2K1C group (Table 1). 
3.7. Kefir reduces oxidative stress in 2K1C hypertensive rat aorta 
The relative contribution of the ROS derived from NADPH oxidase 
in the ACh-induced relaxation was evaluated using apocynin. 
Regarding the maximum response, as shown in Fig. 7 (left panel), in-
cubation with apocynin did not alter the relaxation (Rmax) in the aortic 
rings from the Sham group (before blockade: 81  ±  8 vs. after: 
81  ±  7%) but significantly increased relaxation in t the 2K1C group 
(from 42  ±  4 to 58  ±  3%, p  <  0.05, middle panel). Interestingly, 
treatment with kefir restored this abnormality (before blockade: 
78  ±  8% vs. after: 78  ±  8%, Fig. 7-right panel), suggesting a vascular 
antioxidant effect. The ΔAUC analysis of the effects of ROS blockade 
showed an increased value in the 2K1C group (ΔAUC: 85  ±  9 a.u.), 
compared with Sham animals (AUC: 26  ±  4 a.u., p  <  0.05), and the 
treatment of hypertensive animals with kefir restored the values 
(32  ±  3 a.u., p  <  0.05) close to the values observed in Sham animals 
(Fig. 7, Table 1). The sensitivity parameter was significantly augmented 
by ROS blockade only in the 2K1C group, and it was restored by kefir 
treatment (before blockade: 7.8  ±  0.3 vs. after: 8.4  ±  0.2, 
p  <  0.05). 
3.8. Determination of %O2− and H2O2 levels in blood cells and endothelial 
aortic cells 
To quantify the bioavailability of %O2- and H2O2 in whole blood cells 
and endothelial aortic cells, we used flow cytometry with DHE and DCF 
indicators (respectively) in all groups. As summarized in Fig. 8 (left 
panel), we observed an increase in ROS blood production in 2K1C an-
imals (DHE: 929  ±  86, DCF: 551  ±  42 a.u.) compared to the Sham 
group (DHE: 516  ±  60, DCF: 252  ±  5 a.u., p  <  0.05). According to 
the left panel of Fig. 8, ROS upregulation was also detected in en-
dothelial cells of the aorta in the same hypertensive animals (DHE: 
1771  ±  32, DCF: 562  ±  41 a.u., respectively) compared to the sham 
group (DHE: 1129  ±  85, DCF: 191  ±  2, a.u., p  <  0.05). Interest-
ingly, kefir supplementation prevented the ROS increase both in the 
blood (reduction of DHE: 60% and DCF: 53%, p  <  0.05) and in the 
aortic cells (reduction of DHE: 61% and DCF: 65%, p  <  0.05). 
3.9. Kefir improves the balance vasodilation and vasoconstriction in the 
prostanoid pathway in 2K1C hypertensive rat aorta 
To evaluate the arachidonic acid-Cox pathway and the influence of 
prostanoids on vascular responsiveness, some aortic rings were pre-
incubated with indomethacin, followed by the construction of con-
centration-response curves to ACh (Fig. 9, Table 1). In the Sham group, 
no difference was found between pre- and post-blockade, since in-
domethacin did not modify the relaxation of the rings (Fig. 9, Table 1). 
On the other hand, the 2K1C group showed a greater relaxation in the 
presence of the Cox blocker, as indicated by the Rmax (48  ±  5% be-
fore blockade vs. 66  ±  4% after, p  <  0.05) and the ΔAUC (87  ±  6 a. 
u.), in comparison to the Sham group (2.9  ±  0.2 a.u., p  <  0.05). This 
suggests an increase in vasoconstrictor prostanoids in the 2K1C 
Fig. 6. Contribution of NO bioavailability to 
endothelial dysfunction in 2K1C cells and 
the effect of kefir treatment. The graphic 
shows the changes in the dose–response to 
Ach (●) following endothelial NO synthase 
blockade (o) with L-NAME (100 μmol/L). 
Each point represents the mean  ±  SEM of 8 
experiments. Statistical significance: 
*p  <  0.05 vs. Sham group (two-way re-
peated measures ANOVA). 
Table 1 
Average values of vascular parameters derived from the concentration–response curves to ACh: Maximum response (Rmax), sensitivity (pEC50) and area under the 
curve (AUC) aiming to investigate the molecular pathways involved in the impaired vasorelaxation in this model of experimental hypertension and the therapeutic 
effectiveness of kefir.         
Parameters Sham 2K1C 2K1C Kefir  
Control Blockade Control Blockade Control Blockade  
NOS blockade effect 
Rmax (%) 81  ±  8 −1.1  ±  0.3a 50  ±  4 5.4  ±  0.4a 62  ±  7 7.2  ±  0.7a 
ΔAUC (a.u.) – 255  ±  11 – 155  ±  9a – 247  ±  8 
pEC50 7.3  ±  0.4 5.5  ±  0.4a 7.0  ±  0.2 7.0  ±  0.3b 7.8  ±  0.5 10  ±  0.3ac 
ROS blockade effect 
Rmax (%) 81  ±  8 81  ±  7 42  ±  4 58  ±  3a 81  ±  9 78  ±  8c 
ΔAUC (a.u.) – 26  ±  4 – 85  ±  9b – 32  ±  3bc 
pEC50 7.5  ±  0.4 7.6  ±  0.6 7.8  ±  0.3 8.4  ±  0.2a 7.1  ±  0.4 6.8  ±  0.4 
COX blockade effect 
Rmax (%) 100  ±  10 99  ±  9 48  ±  5 66  ±  4ab 83  ±  7 91  ±  8c 
ΔAUC (a.u.) – 2.9  ±  0.2 – 87  ±  6b – 5.4  ±  2bc 
pEC50 7.8  ±  0.6 8.2  ±  0.8 7.1  ±  0.3 8.3  ±  0.3a 7.1  ±  0.5 7.4  ±  0.3c 
Values are mean ± SEM. ap  <  0.5 vs. control value into the same group; bp  <  0.05 vs. Sham group; cp  <  0.05 vs. 2K1C group.  
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pathway, but not in 2K1C treated with kefir, which demonstrated dis-
creet participation (Rmax after blockade: 91  ±  8% and ΔAUC: 
5.4  ±  2 a. u, p  <  0.05). Following the same protocol, Cox pathway 
blockade caused a significant increase in the sensitivity in the 2K1C 
group (from 7.1  ±  0.3% to 8.3  ±  0.3%) but not in the Sham and 
2K1C-Kefir groups (Fig. 9, Table 1). 
4. Discussion 
In the last two decades, the abrupt jump in the number of scientific 
publications (i.e., from 13 in 2001 to 7725 papers in 2019) has gen-
erated extraordinary new knowledge and simultaneously clarified many 
unanswered questions about the interaction between the gut microbiota 
and the function of the organs and systems in health and diseases 
(Companys et al., 2020; Khalesi et al., 2019). Moreover, there is a 
consensual opinion that probiotic supplementation contributes to pre-
venting chronic disorders, including cardiovascular diseases (Pimenta 
et al., 2018). On the other hand, even with important advances, there is 
still a large step needed to further understand the contribution of pro-
biotic consumption in the potential protective effectiveness in cardio-
vascular diseases (Peng, Xiao, Hu, & Zhang, 2018). In parallel, a 
growing number of studies are designed to study the beneficial effects 
of prebiotics and probiotics targeting disorders in the cardiovascular 
system, such as cardiac dysautonomia and abnormal vascular respon-
siveness (Friques et al., 2020; Klippel et al., 2016). On the other hand, 
there are many open questions that need to be clarified, as recently 
stated by Sanders, Merenstein, Reid, Gibson, and Rastall (2019); despite 
important advances, more research and translational efforts on pre-
biotics and probiotics are still needed (Khalesi et al., 2019; Sanders 
et al., 2019). 
This study was designed to investigate the possible protective effects 
of chronic supplementation with the probiotic kefir on the cardiovas-
cular-renal system in the 2K1C model. The main beneficial effects ob-
served in this study and discussed below are (a) a moderate decrease in 
high blood pressure, (b) reduction of Ang II levels in both plasma and 
kidney tissue, (c) improvement of vascular endothelial responsiveness 
to ACh and (d) protective role in the architecture of nephron segments 
and aorta endothelial surface. 
Our experimental design was inspired by previous data from our 
laboratory and from other research groups. First, several studies have 
shown that changes in the composition of the gut microbiota in murine 
models and humans may contribute to the development of arterial 
hypertension (Bellikci-Koyu et al., 2019; Honour, 1982; Jama, Kaye, & 
Marques, 2019; Tang, Kitai, & Hazen, 2017; Venkatakrishnan, Chiu, & 
Wang, 2020). This is in agreement with recent data demonstrating that 
the oral administration of kefir reduces arterial pressure in both SHR 
Fig. 7. Contribution of NADPH oxidase- 
generated ROS to endothelial dysfunction in 
2K1C cells and the effect of kefir treatment. 
Concentration-response curves induced by 
Ach in rat aortic rings in the absence (●) or 
in the presence (o) of apocynin (100 μmol/ 
L). Each point represents the mean  ±  SEM 
of 8 experiments. Statistical significance: 
*p  <  0.05 vs. Sham group (two-way re-
peated measures ANOVA). 
Fig. 8. Kefir prevents ROS production in 
blood and endothelial aortic cells in rats 
with renovascular hypertension. Graphical 
representation of flow cytometry showing 
the fluorescence intensity of DHE and DCF 
with severe overproduction of %O2- and 
H2O2 in the 2K1C groups, being which was 
completely reversed by kefir supplementa-
tion in both samples. Values are presented 
as the mean  ±  SEM for n = 4–6 animals 
per group. *p  <  0.05 vs. control group and 
#p  <  0.05 vs. 2K1C group (one-way 
ANOVA). 
Fig. 9. Contributions of prostanoids to the ef-
fect of kefir on endothelial dysfunction in re-
novascular hypertensive rats. Concentration- 
response curves induced by Ach in rat aortic 
rings in the absence (●) or in the presence (o) 
of indomethacin (10 μmol/L). Each point re-
presents the mean  ±  SEM of 8 experiments. 
Statistical significance: *p  <  0.05 vs. Sham 
group (two-way repeated measures ANOVA). 
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(model of primary hypertension) (de Almeida Silva et al., 2020; Friques 
et al., 2015; Tang et al., 2017) and 2K1C rats (a model of secondary 
hypertension) (Amorim et al., 2019). Moreover, recent studies have 
shown that kefir administration results in attenuated endothelial dys-
function and improves baroreflex control of arterial pressure, probably 
by antioxidative and anti-inflammatory actions (Brasil et al., 2018; de 
Almeida Silva et al., 2020; Friques et al., 2015). However, it is difficult 
to accurately determine a major mechanism of action of a probiotic that 
has beneficial effects in diverse diseases. Our alternative strategy was to 
study the impact of this probiotic in the 2K1C rat, an experimental 
model mostly dependent on Ang II (Campos et al., 2015; Herrmann & 
Textor, 2019; Navar et al., 1998; Pereira et al., 2009). 
Interestingly, while kefir lowered blood pressure only after 60 days 
of treatment (Friques et al., 2015), Our current investigation demon-
strated that 2K1C rats treated with the same low dose of kefir achieved 
early antihypertensive efficacy (from 28 days), providing further in-
sight into the mechanisms of its antihypertensive properties. Interesting 
that 1) RAS plays an important role in the maintenance of 2K1C hy-
pertension (Campos et al., 2015; Herrmann & Textor, 2019; Navar 
et al., 1998; Pereira et al., 2009), 2) ACE activity in serum and tissues 
significantly increases during the development of RH (Okamura, 
Miyazaki, Inagami, & Toda, 1986; Sharifi, Akbarloo, Heshmatian, & 
Ziai, 2003); and 3) kefir peptides are capable of inhibiting ACE activity 
in silico and in vivo using proteomic and pharmacological approaches, 
respectively (Amorim et al., 2019). We suggest that kefir may exhibit 
characteristics of an effective ‘captopril-like’ nutraceutical, justifying 
our investigation in this chronic hypertensive Ang II-dependent model. 
ACE is a decapeptidyl peptidase that catalyzes the degradation of 
bradykinin to inactive fragments (reducing the serum levels of en-
dogenous vasodilators) (Ferreira, 2000; Ferreira, Greene, Alabaster, 
Bakhle, & Vane, 1970). At the same time, it catalyzes Ang II production, 
contributing directly to the increase in arterial pressure via com-
plementary mechanisms (through AT1 receptors), including vasocon-
striction, sympathoexcitation coupled with aldosterone and vasopressin 
release under the influence of oxidative stress (Campos et al., 2015; 
Lavoie & Sigmund, 2003; Peotta, Gava, Vasquez, & Meyrelles, 2007). 
Confirming our hypothesis, we found that both ACE activity and Ang II 
bioavailability (in both blood and contralateral/clipped kidneys) were 
decreased in the 2K1C group treated with kefir. These data corroborate 
recent findings by Amorim et al. (2019) from our laboratory, suggesting 
that several peptide candidates found in kefir could act as ACE in-
hibitors, justifying the impact of this ‘captopril-like’ probiotic in target 
organs, such as kidneys and systemic arteries, as discussed below. 
Regarding the renal parameters, previous studies have already de-
monstrated some nephroprotective properties of kefir in different ex-
perimental models (diabetes, low-dose aspirin, ischemia-reperfusion 
injury), observing improvement in renal function, probably due to an-
tioxidative effects exhibited by this probiotic, although by unknown 
mechanisms (Kanbak et al., 2014; Punaro et al., 2014; Yener et al., 
2015). In the present study, we performed morphological analysis of 
clipped and nonclipped kidneys through scanning electron microscopy. 
The typical images (Fig. 3) revealed a clear integrity of glomerulus, 
podocytes and kidney tubules in the 2K1C hypertensive rats treated 
with kefir when compared with the structural damage observed in some 
nontreated 2K1C rats exposed to high levels of plasma and intrarenal 
Ang II, corroborating other studies (Dias et al., 2014; Pereira et al., 
2009; Satou, Penrose, & Navar, 2018). Therefore, we suggest that due 
to the ‘captopril like’ effect, the pro-oxidative and pro-inflammatory 
effects of Ang II might be partially antagonized by kefir, reflecting a 
diminished glomerular and tubular injury in RH, despite the main-
tenance of mass of clipped and nonclipped kidneys. Although mor-
phological analysis of the kidneys was not the main focus of this study, 
these exciting findings open new avenues for investigation of renal 
function. In this regard, further protocols such as specific staining tools, 
renal address biomarkers (urea, creatinine and cystatin C), glomerular 
filtration rate and renal plasma flow need to be designed to clearly 
detail these questions. 
Endothelial dysfunction is an important biomarker of vascular da-
mage commonly observed in high blood pressure and neuro-humoral 
factors (Choi et al., 2014; Dias et al., 2014; Fahning et al., 2015; 
Konukoglu & Uzun, 2017; Schäfer et al., 2012; Vanhoutte, Shimokawa, 
Tang, & Feletou, 2009; Vasquez et al., 2016, 2020), such as in the 
present model. In this context, previous data have shown that upregu-
lation of the ACE/Ang axis culminates with the impairment of en-
dothelium-dependent relaxation to ACh and hyperresponsiveness to 
norepinephrine. These abnormalities are accompanied by a marked 
decrease in NO bioavailability (triggered by ROS generation) and im-
proved vasoconstriction to prostanoids (Choi et al., 2014; Dias et al., 
2014; Schäfer et al., 2012). In the current study, we evaluated the ef-
fects of kefir treatment on endothelial dysfunction in hypertensive 
2K1C rats. First, endothelium-dependent (to ACh) and endothelium- 
independent relaxation (to SNP) were diminished in 2K1C rats, in-
dicating that vascular damage may be due to impaired function linked 
to molecular signaling in both endothelial cells (frequently observed in 
this model) and vascular smooth muscle cells (rarely observed in this 
model) (Choi et al., 2016; Lee et al., 1995). The novel finding is that 
kefir helped to protect these two layers of the aorta, as indicated by the 
parameters of the dose–response curve to ACh and SNP (Fig. 5). This 
differs from what we have observed in SHR rats treated with kefir de-
monstrating a protective effect only in endothelial surface cells (Friques 
et al., 2015). In addition, we found hypercontractility in aortic rings 
from 2K1C, which was attenuated by kefir (Fig. 5). To investigate 
possible mechanisms that may explain the vascular beneficial effects of 
kefir and the partial recovery of the architecture of the endothelial 
surface, we designed standard protocols using pharmacological in-
hibitors to assess the relative contribution of each ACh-dependent 
molecular pathway. 
It is well known that along artery segments, there is a varying 
participation of vasoactive substances (e.g., NO, ROS, prostanoids, en-
dothelium-derived hyperpolarizing factor) (Bolz, de Wit, & Pohl, 1999; 
Dias et al., 2014; Goto & Kitazono, 2019; Meyrelles, Peotta, Pereira, & 
Vasquez, 2011). Moreover, studies have demonstrated that NO is the 
main contributor to vasodilation in the aorta of rats, justifying our in-
vestigation of downstream-related pathways. Corroborating these pre-
vious studies, our protocol using L-NAME emphasizes that the impair-
ment of NO/cGMP signaling is the primary contributor to vascular 
damage (observed by abolition of vasodilator response), and interest-
ingly, the vascular protection generated by kefir is highly NO-depen-
dent. In addition, since previous studies have shown the involvement of 
NO physiological antagonists such as ROS and vasoconstrictor prosta-
noids in Ang II-dependent hypertensive animals (Choi et al., 2016; Dias 
et al., 2018; Leal et al., 2017; Virdis, Duranti, & Taddei, 2011), we 
performed complementary procedures in our study. After blockade of 
the main source of ROS with apocynin (an NADPH oxidase inhibitor), 
we noted a significant improvement in the partial endothelium-de-
pendent relaxation induced by ACh in 2K1C aortic rings. Thus, our 
results are in agreement with others that demonstrated a relevant 
participation of the Ang II/AT1/NADPH oxidase/ROS axis in RH 
(Campos et al., 2011; Choi et al., 2014; Dias et al., 2014; Virdis et al., 
2011). Despite the relevant results observed in the present data, further 
studies are needed to evaluate whether the above results can be re-
produced in resistance arteries and to determine the possible con-
tribution of the EDH/EDHF pathways in this process. In agreement with 
the vascular reactivity, our findings using flow cytometry also sup-
ported the antioxidant properties of chronic kefir supplementation, 
both at systemic and local levels, as we recently reported (Friques et al., 
2015, 2020; Ton et al., 2020) and others (Fahmy & Ismail, 2015). Al-
though recent data have shown that kefir grain fermentation has in-
trinsic antioxidant activities (justified by chelation of transition metals 
by lactoferrin/albumin or free radical scavenging by tyrosine/cysteine) 
(Hernández-Ledesma, Amigo, Ramos, & Recio, 2004; Sabokbar & 
Khodaiyan, 2016), we hypothesized that the ‘captopril-like’ effect 
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promoted by kefir might be another important factor to antagonize the 
prooxidant and harmful influences of Ang II in hypertension. Moreover, 
we consider that in addition to the AT1/NADPH pathway, com-
plementary mechanisms have been recently proposed, such as the di-
rect generation of mitochondrial ROS via mitochondrial Ang II inter-
nalized via AT1 receptors (Vajapey, Rini, Walston, & Abadir, 2014; 
Valenzuela et al., 2016). However, regardless of the activation me-
chanism, the antioxidant effect provided by this nutraceutical seems 
extremely attractive for hypertension control, mainly in patients re-
fractory to antihypertensive medications. 
In addition, since previous studies suggested that Ang II mediated 
by ROS production could stimulate COX-1 activity and consequently 
lead to an increase in vasoconstrictor prostanoids (e.g., PGH2, TXA2) 
(Leal et al., 2017; Schäfer et al., 2012; Virdis et al., 2007, 2011), we 
explored this pathway using a Cox inhibitor and indirectly observed 
their contributions to the relaxation response induced by ACh in all 
groups. Interestingly, indomethacin partially ameliorated the Ang II- 
induced endothelial dysfunction only in 2K1C animals, corroborating 
previous data (Schäfer et al., 2012; Virdis et al., 2007, 2011). For-
tunately, 2K1C treated with kefir was able to abolish this difference, 
contributing even more to its vascular protective effects against hy-
pertension-associated complications (Vasquez et al., 2019). 
A further design should include an analysis of the physiological 
parameters of the kidneys (blood flow and glomerular filtration) and 
potential biomarkers of glomerular and tubular damage. In addition, 
due to the important ‘captopril-like’ effect of this probiotic, the bra-
dykinin pathway needs to be investigated in this experimental model. 
The hypothesis to be tested is that, at least in part, the cardiovascular 
protective effects could be triggered by the accumulation of bradykinin 
and not only by reductions in the harmful effects of Ang II. 
5. Conclusion 
This study is the first to demonstrate that probiotic supplementation 
with kefir, even at a low dose, was able to decrease the Ang II-depen-
dent high blood pressure in 2K1C rats early. The data show that the 
hypotensive effects of kefir seem to occur, at least in part, via ACE-Ang 
II inhibition. As summarized in Fig. 10, other remarkable beneficial 
effects included the improvement of nephron structure, endothelial 
dysfunction, attenuation of the high levels of ROS in the plasma and 
kidney tissues and attenuation of damage to the architecture of the 
aortic endothelial surface. These findings suggest that kefir (and prob-
ably other probiotics) is a promising coadjuvant nutraceutical against 
the progression of hypertension. 
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